Clinical Value of Serum Interleukin-18 in Neonatal Sepsis Diagnosis and Mortality Prediction
Xiaojuan Li,Tiewei Li,Geng Dong,Yulei Wei,Zhe Xu,Junmei Yang
DOI: https://doi.org/10.2147/JIR.S393506
IF: 4.5
2022-12-30
Journal of Inflammation Research
Abstract:Xiaojuan Li, Tiewei Li, Geng Dong, Yulei Wei, Zhe Xu, Junmei Yang Zhengzhou Key Laboratory of Children's Infection and Immunity, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, People's Republic of China Correspondence: Tiewei Li, Email Purpose: Previous studies have demonstrated that interleukin-18 (IL-18) levels were elevated in adult patients with sepsis. However, its role in neonatal sepsis remains unknown. The current research was conducted to assess the clinical value of serum IL-18 level as a candidate biomarker in neonatal sepsis diagnosis and prediction of mortality. Patients and Methods: From July 2022 to September 2022, we prospectively enrolled 91 septic neonates and 31 non-sepsis neonates in the intensive care unit of neonates at Henan Children's Hospital in Zhengzhou, China. Neonatal peripheral blood serum was collected at admission and levels of serum IL-18 were assessed. Employing multivariate logistic regression analysis, the evaluation of the potential of IL-18 as an independent biomarker for sepsis was executed. Furthermore, employing the receiver operating characteristic (ROC) curve analysis, the diagnostic value of IL-18 in sepsis and the ability of IL-18 in predicting the mortality of neonatal sepsis was measured. The statistical package SPSS 24.0 was employed to conduct all statistical analyses. Results: Serum IL-18 levels in neonates in the sepsis group were elevated compared to the control group, reaching the highest levels in the non-survival sepsis group (P < 0.001). Correlation analysis exhibited a positive relationship between IL-18 levels and age, body temperature, respiratory rate, and C-reactive protein levels. IL-18 was identified as an independent biomarker in identifying sepsis (OR = 4.747, 95% CI 1.493– 15.092, P = 0.008) by multiple logistic regression. ROC curve analysis exhibited that IL-18 was good in identifying neonatal sepsis (area under curve (AUC) = 0.77, 95% CI = 0.68– 0.85, P < 0.001) and predicting neonatal mortality (AUC = 0.80, 95% CI = 0.63– 0.96, P = 0.003). Conclusion: IL-18 was a potential biomarker for identifying neonatal sepsis and neonatal mortality prediction. Keywords: interleukin-18, neonatal sepsis, mortality Neonatal sepsis is a severe bloodstream infection associated with a systemic inflammatory response that seriously threatens the health and life of neonates worldwide. 1 A population-level estimate of neonatal sepsis, with a death rate in the range of 11% and 19%, was found in an epidemiological study to be 2202 per 100000 live births. 2 Neonatal sepsis remains a leading cause of morbidity and mortality in infants worldwide. 3–5 Surviving Sepsis Campaign Physician's management guidelines promote early sepsis identification, as well as treatment. 6 Traditionally, confirmed neonatal sepsis is diagnosed by isolating pathogens from sterile body fluids, such as blood, cerebrospinal fluid, and urine. However, the isolation of pathogens from sterile body fluids usually has a long waiting time and the accuracy is easily affected by the volume of body fluids and the pre-hospital antibiotic use. 7 Therefore, it is critical to identify new biomarkers for neonatal sepsis. Uncontrolled inflammatory response play an important role in sepsis-induced multiple organ dysfunction. 8 As a pro-inflammatory cytokine, Interleukin-18 (IL-18) is an important effector during sepsis, which is crucial for host defense against bacteria, viruses, and fungi. 9,10 Upon stimulation, several cell types produce IL-18. 11 Excessive IL-18 can aggravate the body's inflammatory response and induce myocardial and kidney injury. 12,13 Okuhara Y et al 14 demonstrated that deletion of IL-18 could improve cardiac dysfunction and survival during sepsis. Clinical studies showed that serum IL-18 levels were up-regulated in adult patients with sepsis. 15,16 In terms of neonates, only one study reported that salivary IL-18 level was not a viable biomarker for the early neonatal sepsis diagnosis, 17 while there has not been any research on the relationship between serum IL-18 levels and neonatal sepsis. Accordingly, we envisioned in the present research to evaluate the clinical value of serum IL-18 level for its application as a potential biomarker in neonatal sepsis diagnosis and predicting mortality. During July 2022 to September 2022, the prospective case-control research was performed in the intensive care unit of neonates at Henan Children's Hospital in Zhengzhou, China, which included 122 neonates with probable sepsis. The inclusion criteria for this study were (1) neonates aged ≤ 28 days, a -Abstract Truncated-
immunology